(UroToday.com) In the Top Abstracts session of the 2021 International Kidney Cancer Symposium (IKCS): North America meeting, Dr. Tannir presented work, based on the CheckMate214 trial, examining long-term survival outcomes for patients treated with first-line nivolumab and ipilimumab compared to sunitinib in patients with metastatic renal cell carcinoma (mRCC).

X